FARMERS & MERCHANTS TRUST Co OF LONG BEACH Sells 529 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,226 shares of the medical equipment provider’s stock after selling 529 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Zimmer Biomet were worth $235,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZBH. Equity Investment Corp purchased a new stake in Zimmer Biomet in the 3rd quarter valued at $70,104,000. Hotchkis & Wiley Capital Management LLC raised its holdings in shares of Zimmer Biomet by 49.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after purchasing an additional 577,320 shares during the last quarter. Magnetar Financial LLC lifted its position in shares of Zimmer Biomet by 58.7% during the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock valued at $142,203,000 after purchasing an additional 484,816 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC bought a new stake in Zimmer Biomet in the 3rd quarter worth about $41,588,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $109.65 on Friday. The stock has a fifty day moving average of $107.81 and a 200-day moving average of $107.97. The stock has a market cap of $21.83 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.67 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the prior year, the business posted $1.65 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Truist Financial lifted their target price on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Royal Bank of Canada increased their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Finally, Evercore ISI lowered their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.